Frank Iorfino1, Elizabeth M Scott1,2, Joanne S Carpenter1, Shane P Cross1, Daniel F Hermens1,3, Madhura Killedar4, Alissa Nichles1, Natalia Zmicerevska1, Django White1, Adam J Guastella1, Jan Scott5, Patrick D McGorry6,7, Ian B Hickie1. 1. Youth Mental Health Team, Brain and Mind Centre, University of Sydney, New South Wales, Australia. 2. The University of Notre Dame, St Vincent's and Mater Clinical School, Sydney, New South Wales, Australia. 3. Sunshine Coast Mind and Neuroscience Thompson Institute, University of the Sunshine Coast, Birtinya, Queensland, Australia. 4. Sydney Informatics Hub, University of Sydney, New South Wales, Australia. 5. Academic Psychiatry, Institute of Neuroscience, Newcastle University, United Kingdom. 6. Orygen, National Centre of Excellence in Youth Mental Health, Melbourne, Australia. 7. Centre for Youth Mental Health, University of Melbourne, Victoria, Australia.
Abstract
Importance: The large contribution of psychiatric disorders to premature death and persistent disability among young people means that earlier identification and enhanced long-term care for those who are most at risk of developing life-threatening or chronic disorders is critical. Clinical staging as an adjunct to diagnosis to address emerging psychiatric disorders has been proposed for young people presenting for care; however, the longer-term utility of this system has not been established. Objectives: To determine the rates of transition from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders and to identify the demographic and clinical characteristics that are associated with the time course of these transitions. Design, Setting, and Participants: A longitudinal, observational study of 2254 persons aged 12 to 25 years who obtained mental health care at 2 early intervention mental health services in Sydney, Australia, and were recruited to a research register between June 18, 2008, and July 24, 2018 (the Brain and Mind Centre Optymise Cohort). Main Outcomes and Measures: The primary outcome of this study was transition from earlier to later clinical stages. A multistate Markov model was used to examine demographic (ie, age, sex, engagement in education, employment, or both) and clinical (ie, social and occupational function, clinical presentation, personal history of mental illness, physical health comorbidities, treatment use, self-harm, suicidal thoughts and behaviors) factors associated with these transitions. Results: Of the 2254 individuals included in the study, mean (SD) age at baseline was 18.18 (3.33) years and 1330 (59.0%) were female. Data on race/ethnicity were not available. Median (interquartile range) follow-up was 14 (5-33) months. Of 685 participants at stage 1a (nonspecific symptoms), 253 (36.9%) transitioned to stage 1b (attenuated syndromes). Transition was associated with lower social functioning (hazard ratio [HR], 0.77; 95% CI, 0.66-0.90), engagement with education, employment, or both (HR, 0.47; 95% CI, 0.25-0.91), manic-like experiences (HR, 2.12; 95% CI, 1.19-3.78), psychotic-like experiences (HR, 2.13; 95% CI, 1.38-3.28), self-harm (HR, 1.42; 95% CI, 1.01-1.99), and older age (HR, 1.27; 95% CI, 1.11-1.45). Of 1370 stage 1b participants, 176 (12.8%) transitioned to stage 2 (full-threshold) disorders. Transition was associated with psychotic-like experiences (HR, 2.31; 95% CI, 1.65-3.23), circadian disturbance (HR, 1.66; 95% CI, 1.17-2.35), psychiatric medication (HR, 1.43; 95% CI, 1.03-1.99), childhood psychiatric disorder (HR, 1.62; 95% CI, 1.03-2.54), and older age (HR, 1.24; 95% CI, 1.05-1.45). Conclusions and Relevance: Differential rates of progression from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders were observed in young persons who presented for care at various stages. Understanding the rate and factors associated with transition assists planning of stage-specific clinical interventions and secondary prevention trials.
Importance: The large contribution of psychiatric disorders to premature death and persistent disability among young people means that earlier identification and enhanced long-term care for those who are most at risk of developing life-threatening or chronic disorders is critical. Clinical staging as an adjunct to diagnosis to address emerging psychiatric disorders has been proposed for young people presenting for care; however, the longer-term utility of this system has not been established. Objectives: To determine the rates of transition from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders and to identify the demographic and clinical characteristics that are associated with the time course of these transitions. Design, Setting, and Participants: A longitudinal, observational study of 2254 persons aged 12 to 25 years who obtained mental health care at 2 early intervention mental health services in Sydney, Australia, and were recruited to a research register between June 18, 2008, and July 24, 2018 (the Brain and Mind Centre Optymise Cohort). Main Outcomes and Measures: The primary outcome of this study was transition from earlier to later clinical stages. A multistate Markov model was used to examine demographic (ie, age, sex, engagement in education, employment, or both) and clinical (ie, social and occupational function, clinical presentation, personal history of mental illness, physical health comorbidities, treatment use, self-harm, suicidal thoughts and behaviors) factors associated with these transitions. Results: Of the 2254 individuals included in the study, mean (SD) age at baseline was 18.18 (3.33) years and 1330 (59.0%) were female. Data on race/ethnicity were not available. Median (interquartile range) follow-up was 14 (5-33) months. Of 685 participants at stage 1a (nonspecific symptoms), 253 (36.9%) transitioned to stage 1b (attenuated syndromes). Transition was associated with lower social functioning (hazard ratio [HR], 0.77; 95% CI, 0.66-0.90), engagement with education, employment, or both (HR, 0.47; 95% CI, 0.25-0.91), manic-like experiences (HR, 2.12; 95% CI, 1.19-3.78), psychotic-like experiences (HR, 2.13; 95% CI, 1.38-3.28), self-harm (HR, 1.42; 95% CI, 1.01-1.99), and older age (HR, 1.27; 95% CI, 1.11-1.45). Of 1370 stage 1b participants, 176 (12.8%) transitioned to stage 2 (full-threshold) disorders. Transition was associated with psychotic-like experiences (HR, 2.31; 95% CI, 1.65-3.23), circadian disturbance (HR, 1.66; 95% CI, 1.17-2.35), psychiatric medication (HR, 1.43; 95% CI, 1.03-1.99), childhood psychiatric disorder (HR, 1.62; 95% CI, 1.03-2.54), and older age (HR, 1.24; 95% CI, 1.05-1.45). Conclusions and Relevance: Differential rates of progression from earlier to later stages of anxiety, mood, psychotic, or comorbid disorders were observed in young persons who presented for care at various stages. Understanding the rate and factors associated with transition assists planning of stage-specific clinical interventions and secondary prevention trials.
Authors: Eóin Killackey; Kelly Allott; Gina Woodhead; Sue Connor; Susan Dragon; Judy Ring Journal: Early Interv Psychiatry Date: 2016-04-28 Impact factor: 2.732
Authors: G Paul Amminger; Miriam R Schäfer; Monika Schlögelhofer; Claudia M Klier; Patrick D McGorry Journal: Nat Commun Date: 2015-08-11 Impact factor: 14.919
Authors: David Fowler; Jo Hodgekins; Paul French; Max Marshall; Nick Freemantle; Paul McCrone; Linda Everard; Anna Lavis; Peter B Jones; Tim Amos; Swaran Singh; Vimal Sharma; Max Birchwood Journal: Lancet Psychiatry Date: 2017-12-11 Impact factor: 27.083
Authors: Jai L Shah; Jan Scott; Patrick D McGorry; Shane P M Cross; Matcheri S Keshavan; Barnaby Nelson; Stephen J Wood; Steven Marwaha; Alison R Yung; Elizabeth M Scott; Dost Öngür; Philippe Conus; Chantal Henry; Ian B Hickie Journal: World Psychiatry Date: 2020-06 Impact factor: 49.548
Authors: Jan Scott; Bruno Etain; David Miklowitz; Jacob J Crouse; Joanne Carpenter; Steven Marwaha; Daniel Smith; Kathleen Merikangas; Ian Hickie Journal: Neurosci Biobehav Rev Date: 2022-02-17 Impact factor: 8.989
Authors: Jacob J Crouse; Nicholas Ho; Jan Scott; Richard Parker; Shin Ho Park; Baptiste Couvy-Duchesne; Brittany L Mitchell; Enda M Byrne; Daniel F Hermens; Sarah E Medland; Nicholas G Martin; Nathan A Gillespie; Ian B Hickie Journal: Eur Psychiatry Date: 2022-06-13 Impact factor: 7.156
Authors: Lani Cupo; Sarah V McIlwaine; Jean-Gabriel Daneault; Ashok K Malla; Srividya N Iyer; Ridha Joober; Jai L Shah Journal: Schizophr Bull Date: 2021-04-29 Impact factor: 9.306
Authors: Sarah Piper; Tracey A Davenport; Haley LaMonica; Antonia Ottavio; Frank Iorfino; Vanessa Wan Sze Cheng; Shane Cross; Grace Yeeun Lee; Elizabeth Scott; Ian B Hickie Journal: BMC Health Serv Res Date: 2021-05-12 Impact factor: 2.655
Authors: Paolo Fusar-Poli; Christoph U Correll; Celso Arango; Michael Berk; Vikram Patel; John P A Ioannidis Journal: World Psychiatry Date: 2021-06 Impact factor: 79.683
Authors: Jan Scott; Jacob J Crouse; Nicholas Ho; Joanne Carpenter; Nicholas Martin; Sarah Medland; Richard Parker; Enda Byrne; Baptiste Couvy-Duchesne; Brittany Mitchell; Kathleen Merikangas; Nathan A Gillespie; Ian Hickie Journal: Bipolar Disord Date: 2021-03-08 Impact factor: 5.345
Authors: M van Doorn; A Popma; T van Amelsvoort; C McEnery; J F Gleeson; F G Ory; Jaspers M W M; M Alvarez-Jimenez; D H Nieman Journal: BMC Psychiatry Date: 2021-07-23 Impact factor: 3.630
Authors: Ralph Kupka; Anne Duffy; Jan Scott; Jorge Almeida; Vicent Balanzá-Martínez; Boris Birmaher; David J Bond; Elisa Brietzke; Ines Chendo; Benicio N Frey; Iria Grande; Danella Hafeman; Tomas Hajek; Manon Hillegers; Marcia Kauer-Sant'Anna; Rodrigo B Mansur; Afra van der Markt; Robert Post; Mauricio Tohen; Hailey Tremain; Gustavo Vazquez; Eduard Vieta; Lakshmi N Yatham; Michael Berk; Martin Alda; Flávio Kapczinski Journal: Bipolar Disord Date: 2021-07-23 Impact factor: 5.345